孟鲁司特钠联合沙美特罗替卡松粉吸入剂治疗老年AECOPD的临床疗效观察

目的观察孟鲁司特钠联合沙美特罗替卡松粉吸人剂（50μg／500μg）（商品名：舒利迭）对老年慢性阻塞性肺疾病急性加重期（AECOPD）的治疗效果。方法112例老年AECOPD患者，随机分为孟鲁司特钠联合舒利迭治疗组56例。对照组56例。治疗14d后，评价所有患者的运动耐力、6min步行距离、痰量、血气分析与肺功能指标第1秒用力呼气容积（FEV1．）、第1秒用力呼气容积占用力肺活量之比（FEV1／FVC）。结果对照组与治疗组上述指标均较治疗前改善（P〈0.05与P〈0．01），但治疗组较对照组改善更为明显（P〈0.05），且药物治疗安全性好。结论孟鲁司特钠联合舒利迭治疗老年AECOPD，疗效显著，能降低运动耐力评分、增加6min步行距离、减少痰量、改善血气分析、促进患者肺功能的恢复。

Clinical observation on montelukast combination with seretide in treatment of elderly patients with AECOPD

Objective To investigate the clinical efficacy of montelukast in combination with seretide in the treatment of elderly patients with AECOPD. Methods A total of 112 elderly patients with AECOPD were randomly divided into two groups ：montelukast in combination with seretide group （n=56）,control group （n=56）.Endurance ratings,6 minutes walking distance, amount of expectoration,blood gas analysis and parameters of pulmonary function（FEV1, FEV1/FVC）of all patients were assessed after 14 days＇treatment. Results Compared with prior treatment, all indicators above of the two group improved a lot（P〈0.05 ,P〈0.01）,but treatment group was even more apparent than control group （P〈0.05）and with a sustained safety. Conclusion Combined montelukast and seretide has a significant effect on the treatment of el- derly patients with AECOPD by decreasing endurance ratings,increasing 6 minutes walking distance,reducing the amount of expectoration, improving blood gas analysis and promoting the recovery of pulmonary function.